Preview

Системные гипертензии

Расширенный поиск

Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022

https://doi.org/10.38109/2075-082X-2022-1-5-22

Полный текст:

Аннотация

Со времени выхода первого консенсуса по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском прошло 3 года. За это время появились новые данные, которые подтверждают важность контроля мочевой кислоты как фактора риска сердечно-сосудистых осложнений и позволяют оптимизировать алгоритм ведения таких пациентов. Исследования, проведенные после выхода первого консенсуса, позволили определить новые пороговые значения гиперурикемии в отношении сердечно-сосудистого риска. Настоящий консенсус регламентирует назначение уратснижающей терапии в зависимости от тяжести выявленной гиперурикемии. Однако несмотря на то, что большая совокупность данных демонстрирует положительное влияние уратснижающей терапии на сердечно-сосудистый прогноз, есть необходимость в дополнительных доказательствах в поддержку лечения бессимптомной гиперурикемии.

Об авторах

И. Е. Чазова
ФГБУ «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Минздрава России
Россия

Чазова Ирина Евгеньевна, д-р мед. наук, проф., акад. РАН, зам. ген. дир. по научно-экспертной работе, рук. отдела гипертонии, НИИ клинической кардиологии им. А.Л. Мясникова

ул. 3-я Черепковская, д. 15а, г. Москва 121552

тел.: +7(495) 415-52-05



Ю. В. Жернакова
ФГБУ «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Минздрава России
Россия

Жернакова Юлия Валерьевна, д-р мед. наук, проф., ученый секретарь НИИ клинической кардиологии им. А.Л. Мясникова

ул. 3-я Черепковская, д. 15а, г. Москва 121552

тел.: +7(495) 414-63-00



О. А. Кисляк
Российский Национальный Исследовательский Медицинский Университет им. Н.И. Пирогова
Россия

Кисляк Оксана Андреевна, д-р мед. наук, проф., зав. каф. факультетской терапии лечебного факультета

ул. Островитянова д. 1, г. Москва 117997



В. И. Подзолков
ФГАОУ Первый МГМУ им. И. М. Сеченова (Сеченовский Университет) МЗ РФ
Россия

Подзолков Валерий Иванович, проф., д-р мед. наук, зав. каф. факультетской терапии №2

ул. Трубецкая, 8 стр. 2, г. Москва 119991



Е. В. Ощепкова
ФГБУ «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Минздрава России
Россия

Ощепкова Елена Владимировна, проф., д-р мед. наук, гл. науч. сотр. отдела гипертонии НИИ клинической кардиологии им.А.Л.Мясникова

ул. 3-я Черепковская, д. 15а, г. Москва 121552

тел.: +7 (495) 414-66-63



О. Ю. Миронова
ФГАОУ Первый МГМУ им. И. М. Сеченова (Сеченовский Университет) МЗ РФ
Россия

Миронова Ольга Юрьевна, д-р мед. наук, проф. каф. факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского

ул. Трубецкая, 8 стр. 2, г. Москва 119991

тел.: +7(499) 248-05-53



Н. В. Блинова
ФГБУ «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Минздрава России
Россия

Блинова Наталия Владимировна, канд. мед. наук, ст. науч. сотр. отдела гипертонии НИИ клинической кардиологии им. А.Л. Мясникова

ул. 3-я Черепковская, д. 15а, г. Москва 121552

тел.: +7(495)414-61-86



Список литературы

1. Bryan Williams, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti Rosei, Michel Azizi, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018 Sep 1; 39(33):3021-3104, https://doi.org/10.1093/eurheartj/ehy339, indexed in Pubmed: 30165516

2. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019; 16(1):6-31 https://doi.org/10.26442/2075082X.2019.1.190179

3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63(10):3136–3141, https://doi.org/10.1002/art.30520, indexed in Pubmed: 21800283

4. Chen-Xu M, Yokose C, Rai SK, et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019; 71(6):991–999, https://doi.org/10.1002/art.40807, indexed in Pubmed: 30618180

5. Kumar AUA, Browne LD, Li X, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohortstudy. PLoS One. 2018; 13(5):e0198197, https://doi.org/10.1371/journal.pone.0198197, indexed in Pubmed: 29852506.

6. Шальнова С.А., Деев А.Д., Артамонова Г.В., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемилогического исследования ЭССЕ-РФ). Рациональная Фармакотерапия в Кардиологии 2014;10(2):153-159 https://doi.org/10.20996/1819-6446-2014-10-2-153-159

7. Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11(11):649–662, https://doi.org/10.1038/nrrheum.2015.91, indexed in Pubmed: 26150127

8. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascularrisk. N Engl J Med. 2008; 359(17):1811–1821, https://doi.org/10.1056/NEJMra0800885, indexed in Pubmed: 18946066

9. Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol. 2005; 25(1):3–8, https://doi.org/10.1016/j.semnephrol.2004.09.002, indexed in Pubmed: 15660328

10. Liu B, Wang T, Zhao HN et al. The prevalence of hyperuricemia in China: a meta-ayalysis. BMC Public Health 2011; 11:832, https://doi.org/10.1186/1471-2458-11-832, indexed in Pubmed: 22032610

11. Hou L, Zhang M, Han W et al. Influence of Salt Intake on Association of Blood Uric Acid with Hypertension and Related Cardiovascular Risk. PLoS One 2016; 11(4):e0150451. https://doi.org/10.1371/journal.pone.0150451, indexed in Pubmed: 27042828

12. Leiba A, Vinker S, Dinour D et al. Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. J Am Soc Hypertens 2015; 9 (8): 600–9. https://doi.org/10.1016/j.jash.2015.05.010, indexed in Pubmed: 26101171

13. Ando K, Takahashi H, Watanabe T et al. Impact of Serum Uric Acid Levels on Coronary Plaque Stability Evaluated Using Integrated Backscatter Intravascular Ultrasound in Patients with Coronary Artery Disease. J Atheroscler Thromb 2016; 23(8):932–9. https://doi.org/10.5551/jat.33951, indexed in Pubmed: 26947600

14. Dai XM, Wei L, Ma LL et al. Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clin Rheumatol 2015; 34(9):1605–11, https://doi.org/10.1007/s10067-015-2878-1, indexed in Pubmed: 25630308

15. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates bloodurate levels. Nature. 2002; 417(6887):447–452, https://doi.org/10.1038/nature742, indexed in Pubmed: 12024214

16. Borghi C. The management of hyperuricemia: back to the pathophysiology of uric acid. Curr Med Res Opin. 2017; 33(sup3):1–4, https://doi.org/10.1080/03007995.2017.1378502, indexed in Pubmed: 28952386

17. De Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr 2012; 4:12. https://doi.org/10.1186/1758-5996-4-12, indexed in PubMed: 22475652

18. Hou L, Zhang M, Han W et al. Influence of Salt Intake on Association of Blood Uric Acid with Hypertension and Related Cardiovascular Risk. PLoS One 2016; 11 (4): e0150451. https://doi.org/10.1371/journal.pone.0150451, indexed in Pubmed: 27042828

19. Ando K, Takahashi H, Watanabe T et al. Impact of Serum Uric Acid Levels on Coronary Plaque Stability Evaluated Using Integrated Backscatter Intravascular Ultrasound in Patients with Coronary Artery Disease. J Atheroscler Thromb 2016; 23(8):932–9. https://doi.org/10.5551/jat.33951, indexed in Pubmed: 26947600

20. Leyva F, Anker S, Swan JW et al. Serum uric acid as an index of impaired oxidative metabolism inchronic heart failure. Eur Heart J 1997; 18(5):858–65. https://doi.org/10.1093/oxfordjournals.eurheartj.a015352, indexed in Pubmed: 9152657

21. Staub M. Uric acid as a scavenger in oxidative stress. Orv Hetil 1999; 140(6):275–279. Hungarian. indexed in Pubmed: 10071505

22. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant – and radical–caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981;78:6858–62. https://doi.org/10.1073/pnas.78.11.6858, indexed in Pubmed: 6947260

23. Tomita М, Mizuno S, Yamanaka H et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10(6):403–409. https://doi.org/10.2188/jea.10.403, indexed in Pubmed: 11210110

24. Agudelo CA, Wise CM. Gout: diagnosis, pathogenesis, and clinical manifestations. Curr Opin Rheumatol 2001; 13 (3): 234–9, https://doi.org/10.1097/00002281-200105000-00015, indexed in Pubmed: 11333355

25. Niskanen LK, Laaksonen DE, Nyyssonen K et al. Uric acid level as a risk factor for cardiovascular and all– cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164:1546-1551, https://doi.org/10.1001/archinte.164.14.1546, indexed in Pubmed: 15277287

26. Mazzali M, Kanellis J, Han L et al. Hyperuricemia inducesa primary arteriolopathy in rats by a blood pressure–independent mechanism. Am J Physiol 2002; 282:F991–F997, https://doi.org/10.1152/ajprenal.00283.2001, indexed in Pubmed: 11997315

27. Su P, Hong L, Zhao Y et al. Relationship Between Hyperuricemia and Cardiovascular Disease Risk Factors in a Chinese Population: A Cross-Sectional Study. Med Sci Monit 2015; 21:2707–17. https://doi.org/10.12659/msm.895448, indexed in Pubmed: 26364955

28. Choi H, Kim HC, Song BM et al. Serum uric acid concentration and metabolic syndrome among elderly Koreans: The Korean Urban Rural Elderly (KURE) study. Arch Gerontol Geriatr 2016; 64:51–8. https://doi.org/10.1016/j.archger.2016.01.005, indexed in Pubmed: 26952377

29. Reginato AM, Mount DB, Yang I, et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012; 8(10):610–621, https://doi.org/10.1038/nrrheum.2012.144, indexed in Pubmed: 22945592.

30. Nigam SK, Bush KT, Martovetsky G, et al. The organic anion transporter (OAT) family: a systems biology perspective. Physiol Rev. 2015; 95(1):83–123, https://doi.org/10.1152/physrev.00025.2013, indexed in Pubmed: 25540139

31. Xu L, Shi Y, Zhuang S, et al. Recent advances on uric acid transporters. Oncotarget. 2017; 8(59):100852– 100862, https://doi.org/10.18632/oncotarget.20135, indexed in Pubmed: 29246027

32. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics. 2008; 40(4):437–442, https://doi.org/10.1038/ng.106

33. Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urateexcretion is a common cause of hyperuricemia. Nat Commun. 2012; 3:764, https://doi.org/10.1038/ncomms1756, indexed in Pubmed: 22473008

34. Ristic B, Sivaprakasam S, Narayanan M, et al. Hereditary hemochromatosis disrupts uric acid homeostasis and causes hyperuricemia via altered expression/activity of xanthine oxidase andABCG2. Biochem J. 2020; 477(8):1499–1513, https://doi.org/10.1042/BCJ20190873, indexed in Pubmed: 32239172

35. Drabkin M, Yogev Y, Zeller L, et al. Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase. J ClinInvest. 2019; 129(12):5163–5168, https://doi.org/10.1172/JCI129057, indexed in Pubmed: 31638601

36. Torres RJ, Puig JG. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2007; 2:48, https://doi.org/10.1186/1750-1172-2-48, indexed in Pubmed: 18067674

37. Belostotsky R, Ben-Shalom E, Rinat C, et al. Mutations in themitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis,HUPRA syndrome. Am J Hum Genet. 2011; 88(2):193–200, https://doi.org/10.1016/j.ajhg.2010.12.010, indexed in Pubmed: 21255763

38. Chung HY, Baek BS, Song SH, et al. Xanthine dehydrogenase//xanthine oxidase and oxidative stress. Age (Omaha). 1997; 20(3):127–140, https://doi.org/10.1007/s11357-997-0012-2, indexed in Pubmed: 23604305

39. Arlot ME, Meunier PJ. Effects of two diphosphonates (EHDP and Cl2MDP) on serum uric acid in pagetic patients. Calcif Tissue Int. 1981; 33(3):195–198, https://doi.org/10.1007/BF02409437, indexed in Pubmed: 6456054.

40. Puig JG, Mateos FA. Clinical and biochemical aspects of uric acid overproduction. Pharm World Sci. 1994; 16(2):40–54, https://doi.org/1007/BF01880655, indexed in Pubmed: 8032341

41. Dong H, Xu Y, Zhang X, et al. Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes. Sci Rep. 2017; 7(1):8822, https://doi.org/10.1038/s41598-017-09455-z, indexed in Pubmed: 28821853

42. Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002; 47(6):610–613, https://doi.org/10.1002/art.10792, indexed in Pubmed: 12522834.

43. Prasad M, Matteson EL, Herrmann J et al. Uric acid is associated with inflammation, coronary microvascular dysfunction, and adverse outcomes in postmenopausal women. Hypertension 2017; 69(2):236–42. https://doi.org/10.1161/HYPERTENSIONAHA.116.08436, indexed in PubMed: 27993955

44. Farquharson CA et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106(2):221–6, https://doi.org/10.1161/01.cir.0000022140.61460.1d, indexed in PubMed: 12105162

45. Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40(3):355–60, https://doi.org/10.1161/01.hyp.0000028589.66335.aa, indexed in PubMed: 12215479

46. Lin C, Zhang Pu, Xue Y et al. Link of renal microcirculatory dysfunction to increased coronary microcirculatory resistance in hypertensive patients. Cardiol J 2017; 24(6):623–32. https://doi.org/10.5603/CJ.a2017.0074, indexed in PubMed: 28653312

47. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid in¬creases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38(5):1101–6, https://doi.org/10.1161/hy1101.092839, indexed in PubMed: 11711505

48. Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16(12):3553–62. https://doi.org/10.1681/ASN.2005050572, indexed in PubMed: 16251237

49. Corry DB, Eslami P, Yamamoto K et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26(2):269–75. https://doi.org/10.1097/HJH.0b013e3282f240bf, indexed in PubMed: 18192841

50. Kang DH, Han L, Ouyang X et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 2005; 25(5):425–33. https://doi.org/10.1159/000087713, indexed in PubMed: 16113518

51. Feig DI, Nakagawa T, Karumanchi SA et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004; 66(1):281–7. https://doi.org/10.1111/j.1523-1755.2004.00729.x, indexed in PubMed: 15200435

52. Lee JE, Kim YG, Choi YH et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006; 47(5):962–7. https://doi.org/10.1161/01.HYP.0000210550.97398.c2, indexed in PubMed: 16520402.

53. Iseki K, Oshiro S, Tozawa M et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24(6):691–7, https://doi.org/10.1291/hypres.24.691, indexed in PubMed: 11768729

54. Rosolowsky ET, Ficociello LH, Maselli NJ et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008; 3(3):706–13. https://doi.org/10.2215/CJN.04271007, indexed in PubMed: 18272826

55. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact onmetabolic syndrome. J Clin Invest 2004; 114 (12): 1752–61. https://doi.org/10.1172/JCI21625, indexed in PubMed: 15599400

56. Fabbrini E, Serafini M, Baric IC et al. Effect of plasma uric acid on antioxidant capacity, oxidativestress, and insulin sensitivity in obese subjects. Diabetes 2014; 63(3):976–81. https://doi.org/10.2337/db13-1396

57. Grassi D, Desideri G, Di Giacomantonio A et al. Hyperuricemia and cardiovascular risk. High Blood Press Cardiovasc Prev 2014; 21(4):235–42. https://doi.org/10.1007/s40292-014-0046-3

58. Blagojevic-Bucknall M, Mallen C, Muller S et al. The Risk of Gout Among Patients With Sleep Apnea:A Matched Cohort Study. Arthritis Rheum 2019; 71(1):154–60. https://doi.org/10.1002/art.40662

59. Evans PL, Prior JA, Belcher J et al. Obesity, hypertension and diuretic use as risk factors for incidentgout: A systematic review and meta-analysis of cohort studies. Arthritis Res Ther 2018; 20(1):1–15. https://doi.org/10.1186/s13075-018-1612-1

60. Cannon PJ, Stason WB, Demartini FE et al. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275(9):457–64. https://doi.org/10.1056/NEJM196609012750902, indexed in PubMed: 5917940

61. Ford ES, Li C, Cook S et al. Serum concentrations of uric acid and the metabolic syndrome among USchildren and adolescents. Circulation 2007; 115(19):2526–32. https://doi.org/10.1161/CIRCULATIONAHA.106.657627, indexed in PubMed: 17470699

62. Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008; 20(2):187–91. https://doi.org/10.1097/BOR.0b013e3282f4b1ed, indexed in PubMed: 18349749

63. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol 2001; 87(12):1411–4, https://doi.org/10.1016/s0002-9149(01)01566-1, indexed in PubMed: 11397367

64. Dehghan A, van Hoek M, Sijbrands EJG et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31(2):361–2. https://doi.org/10.2337/dc07-1276, indexed in PubMed: 17977935

65. Schretlen DJ, Inscore AB, Vannorsdall TD et al. Serum uric acid and brain ischemia in normal elderlyadults. Neurology 2007; 69(14):1418–23. https://doi.org/10.1212/01.wnl.0000277468.10236.f1, indexed in PubMed: 17909154

66. Lehto S, Niskanen L, Rönnemaa T et al. Serum uric acid is a strong predictor of stroke in patients withnoninsulin-dependent diabetes mellitus. Stroke 1998; 29(3):635–9, https://doi.org/10.1161/01.str.29.3.635, indexed in PubMed: 9506605

67. Yu KH, Kuo CF, Luo SF et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther 2012; 14(2):R83. https://doi.org/10.1186/ar3806, indexed in PubMed: 22513212

68. Abbott RD, Brand FN, Kannel WB et al. Gout and coronary heart disease: the Framingham Study.J Clin Epidemiol 1988; 41(3):237–42, https://doi.org/10.1016/0895-4356(88)90127-8, indexed in PubMed: 3339376

69. De Vera MA, Rahman MM, Bhole V et al. Independent impact of gout on the risk of acute myocardialinfarction among elderly women: a population-based study. Ann Rheum Dis 2010; 69(6):1162–4.https://doi.org/10.1136/ard.2009.122770, indexed in PubMed: 20124358

70. Borghi C, Rosei EA, Bardin T et al. Serum uric acid and the risk of cardiovascular and renal disease.J Hypertens 2015; 33(9):1729–41. https://doi.org/10.1097/HJH.0000000000000701, indexed in PubMed: 26136207

71. Mackenzie IS, Ford I, Walker A, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open. 2016; 6(9):e013774, https://doi.org/10.1136/bmjopen-2016-013774, indexed in Pubmed: 27609859

72. Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011; 63(1):102–110, https://doi.org/10.1002/acr.20344, indexed in Pubmed: 20824805

73. Bombelli M, Ronchi I, Volpe M, et al. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. J Hypertens. 2014; 32(6):1237–1244, https://doi.org/10.1097/HJH.0000000000000161, indexed in Pubmed: 24675682

74. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007; 49(2):298–303, https://doi.org/10.1161/01.HYP.0000254480.64564.b6, indexed in Pubmed: 17190877

75. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006; 48(6):1031–1036, https://doi.org/10.1161/01.HYP.0000248752.08807.4c, indexed in Pubmed: 17060508

76. Forman JP, Choi H, Curhan GC. Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med. 2009; 169(2):155–162, https://doi.org/10.1001/archinternmed.2008.521, indexed in Pubmed: 19171812

77. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006; 48(6):1037–1042, https://doi.org/10.1161/01.HYP.0000249768.26560.66, indexed in Pubmed: 17060502

78. Zhang W, Sun K, Yang Y, et al. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem. 2009; 55(11):2026–2034, https://doi.org/10.1373/clinchem.2009.124891, indexed in Pubmed: 19729471

79. Shankar A, Klein R, Klein BEK, et al. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J Hum Hypertens. 2006; 20(12):937–945, https://doi.org/10.1038/sj.jhh.1002095, indexed in Pubmed: 17024135

80. Sundström J, Sullivan L, D’Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005; 45(1):28–33, https://doi.org/10.1161/01.HYP.0000150784.92944.9a, indexed in Pubmed:15569852

81. Yü TF, Berger L, Dorph DJ et al. Renal function in gout. V. Fac¬tors influencing the renal hemodynamics. Am J Med 1979; 67(5):766–71, https://doi.org/10.1016/0002-9343(79)90732-0, indexed in PubMed: 507087

82. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991; 59(3):364–8. https://doi.org/10.1159/000186593, indexed in PubMed: 1758523

83. Messerli FH, Frohlich ED, Dreslinski GR et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93(6):817–21, https://doi.org/10.7326/0003-4819-93-6-817, indexed in PubMed: 7447188

84. Alper AB, Chen W, Yau L, et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension. 2005; 45(1):34–38, https://doi.org/10.1161/01.HYP.0000150783.79172.bb, indexed in Pubmed: 15569853

85. Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens. 1999; 13(1):13– 21, https://doi.org/10.1038/sj.jhh.1000740, indexed in Pubmed: 9928747

86. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007; 18(1):287–292, https://doi.org/10.1681/ASN.2006080865, indexed in Pubmed: 17167112

87. Hunt SC, Stephenson SH, Hopkins PN, et al. Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension. 1991; 17(6_pt_2):969–976, https://doi.org/10.1161/01.hyp.17.6.969, indexed in Pubmed: 2045178

88. Imazu M, Yamamoto H, Toyofuku M, et al. Hyperinsulinemia for the development of hypertension: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res. 2001; 24(5):531–536, https://doi.org/10.1291/hypres.24.531, indexed in Pubmed: 11675947

89. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hyper¬tension: the Olivetti heart study. J Hum Hypertens. 1994; 8(9):677–681, indexed in Pubmed: 7807497

90. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007; 49(2):298–303, https://doi.org/10.1161/01.HYP.0000254480.64564.b6, indexed in Pubmed: 17190877

91. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003; 42(4):474–480, https://doi.org/10.1161/01.HYP.0000091371.53502.D3, indexed in Pubmed: 12953019

92. Mellen P, Bleyer A, Erlinger T, et al. Serum Uric Acid Predicts Incident Hypertension in a Biethnic Cohort. Hypertension. 2006; 48(6):1037–1042, https://doi.org/10.1161/01.hyp.0000249768.26560.66

93. Nagahama K, Inoue T, Iseki K, et al. Hyperuricemia as a pre¬dictor of hypertension in a screened cohort in Okinawa, Ja¬pan. Hypertension Res. 2004; 27(11):835–841, https://doi.org/10.1291//hypres.27.835

94. Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens. 2001; 19(7):1209–1215, https://doi.org/10.1097/00004872-200107000-00005, indexed in Pubmed: 11446710

95. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002; 13(12):2888–2897, https://doi.org/10.1097/01.asn.0000034910.58454.fd, indexed in Pubmed: 12444207

96. Lee JE, Kim YG, Choi YH et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006; 47(5):962–7. https://doi.org/10.1161/01.HYP.0000210550.97398.c2, indexed in PubMed: 16520402

97. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007; 25(8):1583–1589, https://doi.org/10.1097/HJH.0b013e32813aeb6c, indexed in Pubmed: 17620953

98. Tatsumi Y, Asayama K, Morimoto A, et al. Hyperuricemia predicts the risk for developing hypertension independent of alcoholdrinking status in men and women: the Saku study. Hypertens Res. 2020; 43(5):442–449, https://doi.org/10.1038/s41440-019-0361-0, indexed in Pubmed: 31776471

99. Ae R, Kanbay M, Kuwabara M. The causality between the serum uric acid level and stroke. Hypertens Res. 2020; 43(4):354–356, https://doi.org/10.1038/s41440-019-0346-z, indexed in Pubmed: 31988480

100. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and metaanalysis. Arthritis Rheum. 2009; 61(7):885–892, https://doi.org/10.1002/art.24612, indexed in Pubmed: 19565556

101. Zhong C, Zhong X, Xu T, et al. Sex-Specific relationship between serum uric acid and risk of stroke: a dose-response meta-analysis of prospective studies. J Am Heart Assoc. 2017; 6(4):e005042, https://doi.org/10.1161/JAHA.116.005042, indexed in Pubmed: 28356280

102. Li J, Muraki I, Imano H, et al. Serum uric acid and risk of stroke and its types: the Circulatory Risk in Communities Study (CIRCS). Hypertens Res. 2020; 43(4):313–321, https://doi.org/10.1038/s41440-019-0385-5, indexed in Pubmed: 31988479

103. Neogi T, Jansen TLTA, Dalbeth N et al. ACR/EULAR CLassification Criteria for Gout. Arthritis Rheum 2015; 67(10):2557–68. https://doi.org/10.1002/art.39254

104. Niskanen LK, Laaksonen DE, Nyyssönen K et al. Uric acid level as a risk factor for cardiovascular andallcause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164(14):1546–51. https://doi.org/10.1001/archinte.164.14.1546, indexed in PubMed: 15277287

105. Yan D, Wang J, Jiang F et al. A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis. Int J Cardiol 2016; 214:194–199. https://doi.org/10.1016/j.ijcard.2016.03.206, indexed in PubMed: 27064641

106. Bove M, Cicero AF, Veronesi M et al. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag 2017; 13:23–28, https://doi.org/10.2147/vhrm.s115080, indexed in PubMed: 28223818

107. Borghi C, Desideri G. Urate-Lowering drugs and prevention of cardiovascular disease: the emerging role of xanthine oxidase inhibition. Hypertension 2016; 67(3):496–8. https://doi.org/10.1161/HYPERTENSIONAHA.115.06531, indexed in PubMed: 26865197

108. Lurbe E, Torro MI, Alvarez-Pitti J et al. Uric acid is linked to cardiometabolic risk factors in overweight and obese youths. J Hypertens 2018; 36(9):1840–6. https://doi.org/10.1097/HJH.0000000000001814, indexed in PubMed: 29916994

109. Jalal DI, Chonchol M, Chen W et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis 2013; 61(1):134–46. https://doi.org/10.1053/j.ajkd.2012.07.021, indexed in PubMed: 23058478.

110. Shadick NA, Kim R, Weiss S et al. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol 2000; 27(7):1708–12, indexed in PubMed: 10914856

111. Li S, Cheng J, Cui L, et al. Cohort study of repeated measurements of serum urate and risk of incident atrial fibrillation. J Am Heart Assoc. 2019; 8(13):e012020, https://doi.org/10.1161/JAHA.119.012020, indexed in Pubmed: 31213103

112. Hong M, Park JW, Yang PS, et al. A mendelian randomization analysis: The causal association between serum uric acid and atrial fibrillation. Eur J Clin Invest. 2020; 50(10):e13300, https://doi.org/10.1111/eci.13300, indexed in Pubmed: 32474920

113. Juraschek SP, Kovell LC, Miller ER et al. Association of kidney disease with prevalent gout in the United States in 1988–1994 and 2007–2010. Semin Arthritis Rheum 2013; 42(6):551–61. https://doi.org/10.1016/j.semarthrit.2012.09.009, indexed in PubMed: 23312548

114. Jing J, Kielstein JT, Schultheiss UT et al. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant 2015; 30(4):613–621. https://doi.org/10.1093/ndt/gfu352, indexed in PubMed: 25395390

115. Johnson RJ, Nakagawa T, Jalal D et al. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 2013; 28(9):2221–8. https://doi.org/10.1093/ndt/gft029, indexed in PubMed: 23543594

116. Hsu Cy, Iribarren C, McCulloch CE et al. Risk factors for end-stage renal disease: 25-year follow-up.Arch Intern Med 2009; 169(4):342–50. https://doi.org/10.1001/archinternmed.2008.605, indexed in PubMed: 19237717

117. Myllymäki J, Honkanen T, Syrjänen J et al. Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. Nephrol Dial Transplant 2005; 20(1):89–95. https://doi.org/10.1093//ndt/gfh584, indexed in PubMed: 15572382

118. Liu P, Chen Y, Wang B et al. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol (Oxf) 2015; 83(4):475–82. https://doi.org/10.1111/cen.12673, indexed in PubMed: 25400252

119. Hart A, Jackson S, Kasiske BL et al. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. Transplantation 2014; 97(10):1066–1071. https://doi.org/10.1097/01.TP.0000440952.29757.66, indexed in PubMed:24503762

120. Bellomo G, Venanzi S, Verdura C et al. Association of uric acid with change in kidney function inhealthy normotensive individuals. Am J Kidney Dis 2010; 56(2):264–72. https://doi.org/10.1053/j.ajkd.2010.01.019, indexed in PubMed: 20385436

121. Obermayr RP, Temml C, Knechtelsdorfer M et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant 2008; 23(4):1265–1273. https://doi.org/10.1093/ndt/gfm790, indexed in PubMed: 18039642

122. Norvik JV, Storhaug HM, Ytrehus K, et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study. BMC Cardiovasc Disord. 2016; 16:85, https://doi.org/10.1186/s12872-016-0265-8, indexed in Pubmed: 27165776

123. Shirasawa T, Ochiai H, Yoshimoto T, et al. Cross-sectional study of associations between normal body weight with central obesity and hyperuricemia in Japan. BMC Endocr Disord. 2020; 20(1):2, https://doi.org/10.1186/s12902-019-0481-1, indexed in Pubmed: 31906920

124. Villegas R, Xiang YB, Elasy T, et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men’s Health Study. Nutr Metab Cardiovasc Dis. 2012; 22(5):409–416, https://doi.org/10.1016/j.numecd.2010.07.012, indexed in Pubmed: 21277179

125. Caliceti C, Calabria D, Roda A, et al. Fructose intake, serum uric acid, and cardiometabolic disorders: a critical review. Nutrients. 2017;9(4), https://doi.org/10.3390/nu9040395, indexed in Pubmed: 28420204

126. Bleyer AJ, Hart TC. Genetic factors associated with gout and hyperuricemia. Adv Chronic Kidney Dis. 2006; 13(2):124–130, https://doi.org/10.1053/j.ackd.2006.01.008, indexed in Pubmed: 16580613

127. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006; 290(3):F625–F631, https://doi.org/10.1152/ajprenal.00140.2005, indexed in Pubmed: 16234313

128. Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, et al. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. J Biol Chem. 2019; 294(11):4272–4281, https://doi.org/10.1074/jbc.RA118.006158, indexed in Pubmed: 30651350

129. Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress andSREBP-1c activation in hepatocytes. Lab Invest. 2014; 94(10):1114–1125, https://doi.org/10.1038/labinvest.2014.98, indexed in Pubmed: 25111690

130. Jang TY, Yeh ML, Huang CI, et al. Association of hyperuricemiawith disease severity in chronic hepatitis C patients. PLoS One.2018; 13(11): e0207043, https://doi.org/10.1371/journal.pone.0207043, indexed in Pubmed: 30395654

131. Petta S, Macaluso FS, Cammà C, et al. Hyperuricaemia: anothermetabolic feature affecting the severity of chronic hepatitis because of HCV infection. Liver Int. 2012; 32(9):1443–1450, https://doi.org/10.1111/j.1478-3231.2012.02842.x, indexed in Pubmed: 22764879

132. Jang TY, Huang CI, Yeh ML, et al. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. J Gastroenterol Hepatol. 2020; 35(3):473–481, https://doi.org/10.1111/jgh.14835, indexed in Pubmed: 31414504

133. Stack AG, Hanley A, Casserly LF et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013; 106(7):647–58. https://doi.org/10.1093/qjmed//hct083, indexed in PubMed: 23564632

134. Ioachimescu AG, Brennan DM, Hoar BM et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008; 58(2):623–30. https://doi.org/10.1002/art.23121, indexed in PubMed: 18240236

135. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116(8):894–900. https://doi.org/10.1161/CIRCULATIONAHA.107.703389, indexed in PubMed: 17698728

136. Kuo CF, See LC, Yu KH et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013; 52(1):127–134. https://doi.org/10.1093/rheumatology/kes223, indexed in PubMed: 22923756

137. Tamariz L, Harzand A, Palacio A et al. Uric acid as a predictor of all-cause mortality in heart failure:a meta-analysis. Congest Heart Fail 2011; 17(1):25–30. https://doi.org/10.1111/j.1751-7133.2011.00200.x, indexed in PubMed: 21272224

138. Thanassoulis G, Brophy JM, Richard H et al. Gout, allopurinol use, and heart failure outcomes. ArchIntern Med 2010; 170 (15):1358–1364. https://doi.org/10.1001/archinternmed.2010.198, indexed in PubMed: 20696962

139. Rumora L, Hlapčić I, Popović-Grle S, et al. Uric acid and uric acid to creatinine ratio in the assessment of chronic obstructive pulmonary disease: Potential biomarkers in multicomponent models comprising IL-1beta. PLoS One. 2020; 15(6):e0234363, https://doi.org/10.1371/journal.pone.0234363, indexed in Pubmed: 32502184

140. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003; 42(3):247– 252, https://doi.org/10.1161/01.HYP.0000085858.66548.59, indexed in Pubmed: 12900431

141. Nakagawa T, Tuttle KR, Short RA, et al. Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol. 2005; 1(2):80–86, https://doi.org/10.1038/ncpneph0019, indexed in Pubmed: 16932373

142. Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and allcause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004; 164(14):1546–1551, https://doi.org/10.1001/archinte.164.14.1546, indexed in Pubmed: 15277287

143. Desideri G, Virdis A, Casiglia E, et al. Exploration into uric and cardiovascular disease: uric acid right for heArt health (URRAH) project, a study protocol for a retrospective observational study. High Blood Press Cardiovasc Prev. 2018; 25(2):197–202, https://doi.org/10.1007/s40292-018-0250-7, indexed in Pubmed: 29427170

144. Virdis A, Masi S, Casiglia E, et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020; 75(2):302–308, https://doi.org/10.1161/HYPERTENSIONAHA.119.13643, indexed in Pubmed: 31813345

145. Perticone M, Tripepi G, Maio R, et al. Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension. Int J Cardiol. 2017; 243:473–478, https://doi.org/10.1016/j.ijcard.2017.05.051, indexed in Pubmed: 28528984

146. Dutta A, Henley W, Pilling LC, et al. Uric acid measurement improves prediction of cardiovascular mortality in later life.J Am Geriatr Soc. 2013; 61(3):319–326, https://doi.org/10.1111/jgs.12149, indexed in Pubmed: 23496291

147. Tscharre M, Herman R, Rohla M, et al. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Atherosclerosis. 2018; 270:173–179, https://doi.org/10.1016/j.atherosclerosis.2018.02.003

148. Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, et al. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2015; 22(4):513–518, https://doi.org/10.1177/2047487313519346, indexed in Pubmed: 24431384

149. Kleber ME, Delgado G, Grammer TB, et al. Uric acid and cardiovascular events: a mendelian randomization study. J Am Soc Nephrol. 2015; 26(11):2831–2838, https://doi.org/10.1681/ASN.2014070660, indexed in Pubmed: 25788527

150. Yan D, Wang J, Jiang F, et al. A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabe tes patients: A Mendelian randomization analysis. Int J Cardiol. 2016; 214:194–199, https://doi.org/10.1016/j.ijcard.2016.03.206, indexed in Pubmed: 27064641

151. Kuwabara M, Borghi C, Cicero AFG, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int J Cardiol. 2018; 261:183–188, https://doi.org/10.1016/j.ijcard.2018.03.045, indexed in Pubmed: 29551256

152. Muiesan ML, Salvetti M, Virdis A, et al. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. J Hypertens. 2021; 39(1):62–69, https://doi.org/10.1097/HJH.0000000000002589, indexed in Pubmed: 32694342

153. Huang G, Qin J, Deng X, et al. Prognostic value of serum uric acid in patients with acute heart failure: A metaanalysis. Medicine (Baltimore). 2019; 98(8):e14525, https://doi.org/10.1097/MD.0000000000014525, indexed in Pubmed: 30813158

154. Casiglia E, Tikhonoff V, Virdis A, et al. Serum uric acid and fatal myocardial infarction: The URRAH (Uric Acid Right for Heart Health) study. J Hypertens. 2020; 38(3):412–419, https://doi.org/10.1097/hjh.0000000000002287, indexed in Pubmed: 31644519

155. Rahimi-Sakak F, Maroofi M, Rahmani J, et al. Serum uric acid and risk of cardiovascular mortality: a systematic review and doseresponse meta-analysis of cohort studies of over a million participants. BMC Cardiovasc Disord. 2019; 19(1):218, https://doi.org/10.1186/s12872-019-1215-z, indexed in Pubmed: 31615412

156. Lee SY, Park W, Suh YJu, et al. Association of serum uric acid with cardiovascular disease risk scores in Koreans. Int J Environ Res Public Health. 2019; 16(23):4632, https://doi.org/10.3390/ijerph16234632, indexed in Pubmed: 31766442

157. Fotherby MD, Potter JF. Metabolic and orthostatic blood pressure responses to a low-sodium diet in elderly hypertensives. J Hum Hypertens 1997; 11(6):361–366, https://doi.org/10.1038/sj.jhh.1000436, indexed in PubMed: 9249230

158. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011; 23(2):192–202. https://doi.org/10.1097/BOR.0b013e3283438e13, indexed in PubMed: 21285714

159. Matsumura K, Arima H, Tominaga M et al. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens 2015; 37(3):192–6. https://doi.org/10.3109/10641963.2014.933968, indexed in PubMed: 25051056

160. Jacob RA, Spinozzi GM, Simon VA et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr 2003; 133(6):1826–9. https://doi.org/10.1093/jn/133.6.1826, indexed in PubMed: 12771324

161. Schlesinger N. Dietary factors and hyperuricaemia. Curr Pharm Des 2005; 11(32):4133–4138, https://doi.org/10.2174/138161205774913273, indexed in PubMed: 16375734

162. Richette P, Poitou C, Manivet P et al. Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. Arthritis Care Res (Hoboken) 2016; 68(7):1036–1042. https://doi.org/10.1002/acr.22798, indexed in PubMed: 26844534

163. Chen JH, Wen CP, Wu SB et al. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis 2015; 74 (11):2034–2042. https://doi.org/10.1136/annrheumdis-2014-205312, indexed in PubMed: 25053714

164. Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019; 9(8):e026677, https://doi.org/10.1136/bmjopen-2018-026677

165. Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1–86.

166. Bardin T, Richette P. FAST: new look at the febuxostat safety profile. Lancet. 2020; 396(10264):1704–1705, https://doi.org/10.1016/S0140-6736(20)32343-6, indexed in Pubmed: 33181079

167. Mackenzie I, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, noninferiority trial. Lancet. 2020; 396(10264):1745–1757, https://doi.org/10.1016/s0140-6736(20)32234-0

168. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378(13):1200–1210, https://doi.org/10.1056/NEJMoa1710895, indexed in Pubmed: 29527974

169. Keenan RT, Pillinger MH. Febuxostat: A new agent for lowering serum urate. Drugs of Today. 2009; 45(4):247, https://doi.org/10.1358/dot.2009.045.004.1354217

170. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostatcompared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23):2450–2461, https://doi.org/10.1056/NEJMoa050373, indexed in Pubmed: 16339094

171. Zhang T, Pope JE. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology (Oxford). 2017; 56(7):1144–1153, https://doi.org/10.1093/rheumatology/kex065, indexed in Pubmed: 28379501

172. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76(1):47–56. https://doi.org/10.1016/0002-9343(84)90743-5, indexed in Pubmed: 6691361

173. Beattie CJ, Fulton RL, Higgins P et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension 2014; 64(5):1102–1107. https://doi.org/10.1161/HYPERTENSIONAHA.114.03953, indexed in PubMed: 25135183

174. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300(8):924–32. https://doi.org/10.1001/jama.300.8.924, indexed in PubMed: 18728266

175. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2013; 15(6):435–442. https://doi.org/10.1111/j.1751-7176.2012.00701.x, indexed in PubMed: 23730993

176. 176. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012; 60(5):1148–1156. https://doi.org/10.1161/HYPERTENSIONAHA.112.196980, indexed in PubMed: 23006736

177. Borghi C, Omboni S, Reggiardo G et al. Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a metaanalysis of individual data of four randomized, double-blind, prospective studies. BMC Cardiovasc Dis 2018; 18(1):112. https://doi.org/10.1186/s12872-018-0800-x, indexed in PubMed: 29866077

178. Luk AJ, Levin GP, Moore EE et al. Allopurinol and mortal¬ity in hyperuricaemic patients. Rheumatology (Oxford) 2009; 48(7):804–6. https://doi.org/10.1093/rheumatology/kep069, indexed in PubMed: 19447769

179. MacIsaac RL, Salatzki J, Higgins P et al. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension 2016; 67(3):535–40. https://doi.org/10.1161/HYPERTENSIONAHA.115.06344, indexed in PubMed: 26865199

180. Wei Li, Mackenzie IS, Chen Y et al. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 2011; 71(4):600–7. https://doi.org/10.1111/j.1365-2125.2010.03887.x, indexed in PubMed: 21395653

181. Noman A, Ang DSC, Ogston S et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375(9732):2161–7. https://doi.org/10.1016/S0140-6736(10)60391-1, indexed in PubMed: 20542554

182. Rekhraj S, Gandy SJ, Szwejkowski BR et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol 2013; 61(9):926–32. https://doi.org/10.1016/j.jacc.2012.09.066, indexed in PubMed: 23449426

183. 158. Higgins P, Dawson J, Lees KR et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther 2012; 30(4):217–26. https://doi.org/10.1111/j.1755-5922.2011.00277.x, indexed in PubMed: 22099531

184. 159. George J, Carr E, Davies J et al. High-dose allopurinol improves endothelial function by profoundlreducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114(23):2508–16. https://doi.org/10.1161/CIRCULATIONAHA.106.651117, indexed in PubMed: 17130343

185. Givertz MM, Anstrom KJ, Redfield MM et al. Effects of Xanthine Oxidase Inhibition in HyperuricemicHeart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation 2015; 131(20):1763–71. https://doi.org/10.1161/CIRCULATIONAHA.114.014536, indexed in PubMed: 25986447

186. Cleland JGF, Coletta AP, Clark AL. Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail 2006; 8(7):764–6. https://doi. org/10.1016/j.ejheart.2006.10.001, indexed in PubMed: 17049305

187. Freudenberger RS, Schwarz RP, Brown J et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III–IV congestive heart failure. Expert Opin Investig Drugs 2004; 13(11):1509–16. https://doi.org/10.1517/13543784.13.11.1509, indexed in PubMed: 15500398

188. George J, Struthers A. The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) trial: a question of dose. J Am Coll Cardiol 2009; 53(25):2405. https://doi.org/10.1016/j.jacc.2008.07.076, indexed in PubMed: 19539154

189. Goicoechea M, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5 (8): 1388–93. https://doi.org/10.2215//CJN.01580210, indexed in PubMed: 20538833

190. Su X, Xu B, Yan B et al. Effects of uric acid-lowering therapy in patients with chronic kidney disease:A meta-analysis. PLoS One 2017; 12(11):e0187550. https://doi.org/10.1371/journal.pone.0187550, indexed in PubMed: 29095953

191. Siu YP, Leung KT, Tong MKH et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47(1):51–9. https://doi.org/10.1053/j.ajkd.2005.10.006, indexed in PubMed: 16377385

192. Sampson AL, Singer RF, Walters GD. Uric acid lowering thera¬pies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev 2017; 10:CD009460. https://doi.org/10.1002/14651858.CD009460.pub2, indexed in PubMed: 29084343

193. Levy GD, Rashid N, Niu F et al. Effect of urate-lowering thera¬pies on renal disease progression in patients with hyperuricemia. J Rheumatol 2014; 41(5):955–62. https://doi.org/10.3899/jrheum.131159, indexed in PubMed: 24692523

194. Richette P, Perez-Ruiz F, Doherty M et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol 2014; 10(11):654–61. https://doi.org/10.1038/nr-rheum.2014.124, indexed in PubMed: 25136785

195. Okafor ON, Farrington K, Gorog DA. Allopurinol as a thera¬peutic option in cardiovascular disease. Pharmacol Ther 2017; 172:139–50. https://doi.org/10.1016/j.pharmthera.2016.12.004, indexed in PubMed: 27916655

196. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58(1):87–114. https://doi.org/10.1124/pr.58.1.6, indexed in PubMed: 16507884

197. Wei L, Fahey T, Struthers AD et al. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract 2009; 63(9):1327–33. https://doi.org/10.1111/j.1742-1241.2009.02118.x, indexed in PubMed: 19691616

198. Dubreuil M, Zhu Y, Zhang Y et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2015; 74(7):1368–72. https://doi.org/10.1136/annrheumdis-2014-205269, indexed in PubMed: 24665118

199. Richette P, Brière C, Hoenen-Clavert V et al. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007; 34(10):2093–2098. http://www.jrheum.org/content/34/10/2093.abstract

200. Solomon DH, Liu C-C, Kuo I-H et al. The Effects of Colchicine on Risk of Cardiovascular Events and Mortality Among Patients with Gout: A Cohort Study Using Electronic Medical Records Linked with Medicare Claims. Ann Rheum Dis 2016; 75(9):1674–9. https://doi.org/110.1016/j.bbi.2017.04.008

201. Solomon DH, Glynn RJ, MacFadyen JG et al. Relationship of Interleukin-1b Blockade With IncidentGout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Ann Intern Med 2018; 169(8):535–42. https://doi.org/10.7326/M18-1167

202. Tran AP, Edelman J. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. IntJ Rheum Dis 2011; 14(3):33–7. https://doi.org/10.1111/j.1756-185X.2011.01629.x

203. Ruoff G, Edwards NL. Overview of serum uric acid treatment targets in gout: why less than 6 mg/dL? Postgrad Med 2016; 128(7):706–15. https://doi.org/10.1080/00325481.2016.1221732, indexed in PubMed: 27558643

204. FitzGerald JD, Mikuls TR, Neogi T et al. Development of the American College of RheumatologyElectronic Clinical Quality Measures for Gout. Arthritis Care Res (Hoboken) 2018; 70(5):659–71. https://doi.org/10.1002/acr.23500, indexed in PubMed: 29649348

205. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76(1):29–42. https://doi.org/10.1136/annrheumdis-2016-209707, indexed in PubMed: 27457514

206. Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology guidelines formanagement of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64 (10):1431–46. https://doi.org/10.1002/acr.21772, indexed in PubMed: 23024028

207. Matsumura K, Arima H, Tominaga M, et al. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens. 2015; 37(3):192–196, https://doi.org/10.3109/10641963.2014.933968, indexed in Pubmed: 25051056

208. Ralston SH, Capell HA, Sturrock RD. Alcohol and response to treatment of gout. Br Med J (Clin Res Ed). 1988; 296(6637):1641–1642, https://doi.org/10.1136/bmj.296.6637.1641-a, indexed in Pubmed: 3135052

209. Neogi T, Dalbeth N, Stamp L, et al. Renal dosing of allopurinol results in suboptimal gout care. Ann Rheum Dis. 2017; 76(1):e1, https://doi.org/10.1136/annrheumdis-2016-210352, indexed in Pubmed:27582422

210. Stamp LK, O’Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011; 63(2):412–421, https://doi.org/10.1002/art.30119, indexed in Pubmed: 21279998

211. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013; 72(6):826–830, https://doi.org/10.1136/annrheumdis-2012-201676, indexed in Pubmed: 22679303

212. Ramasamy SN, Korb-Wells CS, Kannangara DRW, et al. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013; 36(10):953–980, https://doi.org/10.1007/s40264-013-0084-0, indexed in Pubmed: 23873481

213. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013; 93(2):153–158, https://doi.org/10.1038/clpt.2012.209, indexed in Pubmed: 23232549

214. Scirè CA, Rossi C, Punzi L, et al. Change gout: how to deal with this ”silently-developing killer” in everyday clinical practice. Curr Med Res Opin. 2018; 34(8):1411–1417, https://doi.org/10.1080/03007995.2018.1454896, indexed in Pubmed: 29553292

215. Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, doubleblind, placebo-controlledstudy in gout patients with an inadequate response to standardof-care allopurinol (a US-based study). Arthritis Rheumatol. 2017; 69(1):203–212, https://doi.org/10.1002/art.39840, indexed in Pubmed: 27564409

216. Dalbeth N, Jones G, Terkeltaub R, et al. Efficacy and safetyduring extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Res Ther. 2019; 21(1):8, https://doi.org/10.1186/s13075-018-1788-4, indexed in Pubmed: 30616614


Рецензия

Для цитирования:


Чазова И.Е., Жернакова Ю.В., Кисляк О.А., Подзолков В.И., Ощепкова Е.В., Миронова О.Ю., Блинова Н.В. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022. Системные гипертензии. 2022;19(1):5-22. https://doi.org/10.38109/2075-082X-2022-1-5-22

For citation:


Chazova I.E., Zhernakova Yu.V., Kislyak O.A., Podzolkov V.I., Oshchepkova E.V., Mironova O.Yu., Blinova N.V. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5-22. (In Russ.) https://doi.org/10.38109/2075-082X-2022-1-5-22

Просмотров: 55


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)